← All organizations
Highest phase reached
Phase 4
First clinical trial
Oct 1, 2015Last known activity
Nov 30, 2025
Timeline
2000s
- Jun 1, 2008
RemeGen— Founded
Drugs by trial phase (37 distinct, 87 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (19 own, 0 via acquisition)
Phase 2 (14 own, 0 via acquisition)
Phase 1 (3 own, 0 via acquisition)
Indications
Studied for
- Arthritis
- Arthritis, Rheumatoid
- Biliary Tract Neoplasms
- Breast Diseases
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Transitional Cell
- Glomerulonephritis, IGA
- Kidney Diseases
- Lung Neoplasms
- Lupus Erythematosus, Systemic
- Macular Degeneration
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Muscle Weakness
- Myasthenia Gravis
- Neoplasms
- Neuromyelitis Optica
- Sclerosis
- Sjogren's Syndrome
- Stomach Neoplasms
- Syndrome
Recent trials (50)
- NCT07249632Lead sponsorPhase 3Nov 30, 2025
- NCT07100184CollaboratorPhase 2Sep 1, 2025
- NCT07105215Lead sponsorPhase 1/Phase 2Aug 11, 2025
- NCT06962865Lead sponsorPhase 2Jun 30, 2025
- NCT06944496Lead sponsorPhase 3May 15, 2025
- NCT06883630Lead sponsorPhase 1Mar 13, 2025
- NCT06642545Lead sponsorPhase 2Nov 1, 2024
- NCT06630871CollaboratorPhase 2Oct 31, 2024
- NCT06558682CollaboratorN/AOct 20, 2024
- NCT06456567Lead sponsorPhase 3Sep 30, 2024
- NCT06549959Lead sponsorPhase 1Aug 5, 2024
- NCT06456580Lead sponsorPhase 3Jul 17, 2024
- NCT06378242Lead sponsorPhase 1/Phase 2Jun 14, 2024
- NCT05745740Lead sponsorPhase 1/Phase 2Apr 30, 2024
- NCT06389006OfficialPhase 2Apr 29, 2024
Details
- Founded
- Yantai, CN Jun 1, 2008
- Last known activity
- Nov 30, 2025